Ud over imatinib, havde 35% af patienterne tidligere modtaget cytotoksisk kemoterapi, 65% havde tidligere modtaget interferon, og 10% havde tidligere modtaget stamcelletransplantation.
In addition to imatinib, 35% of patients had received prior cytotoxic chemotherapy, 65% had received prior interferon, and 10% had received a prior stem cell transplant.